The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
852
September 6, 1991
View Complete Issue         Table of Contents 2019 
A Drug Prevention of Anthracycline-Induced Cardiac Toxicity
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
A Drug Prevention of Anthracycline-Induced Cardiac Toxicity
September 6, 1991 (Issue: 852)
Recent studies have caused concern about cardiomyopathy associated with doxorubicin (Adriamycin, and others), daunorubicin (Cerubidine, and others), idarubicin (Idamycin), mitoxantrone (Novantrone), and related anthracycline or anthraquinone...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: A Drug Prevention of Anthracycline-Induced Cardiac Toxicity
Article code: 852c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.